Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN
09944-cover1-opener.jpg

December 6, 2021 Cover

Volume 99, Issue 44

This second pandemic year affirmed the drug industry’s strength in tackling public health crises. Headlines in 2021 were dominated by the arrival of COVID-19 vaccines and, recently, antiviral treatments, but pharmaceutical and biotech companies also continued to work on new technologies that could transform care for people with other diseases.

Cover image:This second pandemic year affirmed the drug industry’s strength in tackling public health crises. Headlines in 2021 were dominated by the arrival of COVID-19 vaccines and, recently, antiviral treatments, but pharmaceutical and biotech companies also continued to work on new therapies that could transform care for people with other diseases

Credit: C&EN/shutterstock

Full Article
Volume 99 | Issue 44

All Issues

Quote of the Week

“We knew you could do it, but when you build something big like that, things can go wrong. This didn’t go wrong.”

Thomas Dolan, fusion reactor expert, University of Illinois Urbana-Champaign

  • Navigating career decisions

    Learning when to act quickly and when to slow down and deliberate

  • New superjelly can go from squishy to ultrahard

    The hydrogel could be used in soft robotics, bioelectronics, and biomedical applications

  • Groups seek end to organophosphate pesticides

ADVERTISEMENT
image name
Vaccines

Omicron puts scientists on red alert

Scientists and companies race to study the latest coronavirus variant and what it means for therapies and vaccines

ADVERTISEMENT
ADVERTISEMENT